Coverage
-
July 27, 2020
A Massachusetts federal judge has tossed a securities class action alleging biopharmaceutical company Aveo and its executives misled investors about possible federal approval of a cancer drug, saying the company "explicitly warned the public" about the uncertainty of a clinical trial.
3 other articles on this case.
View all »